ArticleBioengineering & translational medicine2022

Stable nebulization and muco-trapping properties of regdanvimab/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19.

Morgan D McSweeney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.